Healthcare
Revvity, Inc.(RVTY)
Live Price
Offline$100.00
+2.23% today
1Y Change
+5.32%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $9.67B
- Revenue Growth
- +3.7%
- EPS Growth
- -13.7%
- Dividend Yield
- 0.3%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Revvity, Inc. (RVTY) is a Healthcare stock with a market cap of $9.67B and listed on NYSE. The stock last traded around $100.00 and up 5.3% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +3.7%, EPS growth of -13.7%, a dividend yield of 0.3%. What stands out right now is revenue +3.7%, EPS -13.7%, free cash flow -6.2% with operating margin 13.0% and ROIC 2.9%. The dividend is present but secondary, with a yield around 0.3%. Valuation already assumes a fairly strong business story at P/E 40.5 and price/sales 3.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RVTY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+3.7% vs +7.6% peer median
Operating Margin
Below sector median
+13.0% vs +19.4% peer median
P/E
Above sector median
40.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 27, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +3.7% and EPS is at -13.7%, with operating margin around 13.0%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.3%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.9% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 27, 2026 | โ | -1.9% | -0.3% | +11.6% |
2026 Feb 2, 2026 | +8.3% | -5.6% | -4.0% | -10.4% |
2025 Oct 27, 2025 | +3.5% | -0.7% | -4.3% | +3.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RVTY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RVTY Max Drawdown
-30.14%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RVTY and SPY.
Company Overview
Revvity, Inc.
New York Stock Exchange
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
- Leadership
- Prahlad R. Singh
- IPO Date
- Jul 6, 1965
- Employees
- 11.0k
- Street Address
- 77 4th Avenue
- Mailing
- Waltham, MA, 02451
- Region
- Waltham, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 663 6900
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 40.5
- EV/EBITDA
- 16.0
- Price/Sales
- 3.4
- Price/Book
- 1.4
Growth
- Revenue
- +3.7%
- EPS
- -13.7%
- Free Cash Flow
- -6.2%
Profitability
- Gross Margin
- 50.2%
- Operating Margin
- 13.0%
- Net Margin
- 8.5%
- ROE
- 3.2%
- ROIC
- 2.9%
Balance Sheet
- Debt/Equity
- 0.48
- Current Ratio
- 1.68
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.